Development of long COVID as a consequence of the complex relationship between Epstein-Barr virus and our immune system

Ana Banko

doi:10.5937/mp74-47742

Ana Banko Univerzitet u Beogradu, Medicinski fakultet, Institut za mikrobiologiju i imunologiju, Beograd, Srbija

DOI: https://doi.org/10.5937/mp74-47742

Keywords: EBV, SARS-CoV-2, long COVID-19, co-infection, reactivation

Abstract

Introduction: The pathophysiological development of long COVID (LC) is still insufficiently known. However, post infection fatigue syndromes were seen before, among other pathogens including Epstein-Barr virus (EBV). Considering EBV reservoir in COVID-19 patients, this review aims to present current knowledge related to EBV role in development of LC and with the potential diagnostic utility.

EBV infection: Following the primary lytic infection of epithelial oropharyngeal and nasopharyngeal cells EBV establishes very complex mechanism of lifelong survival in B cells. Latent infection with occasional viral reactivations constantly challenge the host immune response. In individuals with immune imbalance including COVID-19, it could drive long-term consequences.

EBV and COVID-19: EBV activity has been shown as the most prevalent human herpesvirus infection in COVID-19 population (41%). Correlation between lymphocytopenia-induced disability to remove the EBV, increases in EBV DNA viremia and COVID-19 complications have also been reported.

EBV and Long COVID: EBV DNA positivity during acute SARS-CoV-2 infection predicted the presence of symptoms at up to 60 days after COVID-19. Association between EBV infection and symptoms such as brain fog, fatigue, arthralgia and skin rashes have been also described in post infection sequelae ME/CFS. Anti-EBV early antigen-diffuse (EA-D) IgG antibodies were detectable among two-thirds of respondents experiencing LC. Increases in anti-EBNA1 IgG levels analyzed months following COVID-19 onset in convalescent LC population could serve as a potential marker of EBV reactivation at the time of acute SARS-CoV-2 infection. Some authors also managed to show anti-EBV viral capsid antigen (VCA) IgM seropositivity in half of COVID-19 patients indicating of either coinfection or EBV reactivation.

Conclusion: LC is a multisystemic illness without defined spectrum of diagnostic and treatment options. Whereas EBV reactivation alone or together with other risk factors drive LC symptoms, further prospective studies involving different cohorts and tissue reservoirs are necessary to understand underlying biological mechanisms.

References

1. Post COVID-19 condition (Long COVID) [Internet]. [cited 2023 Nov 13]. Available from: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition
2. Astin R, Banerjee A, Baker MR, Dani M, Ford E, Hull JH, et al. Long COVID: mechanisms, risk factors and recovery. Exp Physiol. 2023;108(1):12–27.
3. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021;12:698169.
4. Global Burden of Disease Long COVID Collaborators; Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, Blyuss O, Bobkova P, Bonsel G, Borzakova S, Buonsenso D, Butnaru D, Carter A, Chu H, De Rose C, Diab MM, Ekbom E, El Tantawi M, Fomin VT. Estimated Global Proportions of Individuals with Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604–15.
5. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid - Mechanisms, risk factors, and management. BMJ. 2021;374:n1648.
6. Proal A, Marshall T. Myalgic encephalomyelitis/chronic fatigue syndrome in the era of the human microbiome: Persistent pathogens drive chronic symptoms by interfering with host metabolism, gene expression, and immunity. Front Pediatr. 2018;6:373.
7. Poenaru S, Abdallah SJ, Corrales-Medina V, Cowan J. COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Ther Adv Infect Dis. 2021;8:1–16.
8. Vojdani A, Vojdani E, Saidara E, Maes M. Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID. Viruses. 2023;15(2):400.
9. Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: Biology and clinical disease. Cell. 2022;185(20):3652–70.
10. Sternbæk L, Draborg AH, Østerlund MT, Iversen L V., Troelsen L, Theander E, et al. Increased antibody levels to stage-specific Epstein–Barr virus antigens in systemic autoimmune diseases reveal a common pathology. Scand J Clin Lab Invest. 2019;79(1–2):7–16.
11. Shafiee A, Aghajanian S, Athar MMT, Gargari OK. Epstein–Barr virus and COVID-19. J Med Virol. 2022;94(9):4040–2.
12. Cox BS, Alharshawi K, Mena-Palomo I, Lafuse WP, Ariza ME. EBV/HHV-6A dUTPases contribute to myalgic encephalomyelitis/chronic fatigue syndrome pathophysiology by enhancing T FH cell differentiation and extrafollicular activities. JCI Insight. 2022;7(11):e158193.
13. Smith C, Khanna R. Immune regulation of human herpesviruses and its implications for human transplantation. Am J Transplant. 2013;13(SUPPL. 3):9–23.
14. Banko A, Miljanovic D, Cirkovic A. Systematic review with meta-analysis of active herpesvirus infections in patients with COVID-19: Old players on the new field. Int J Infect Dis. 2023;130:108–25.
15. Majtanova N, Kriskova P, Keri P, Fellner Z, Majtan J, Kolar P. Herpes simplex keratitis in patients with SARS-CoV-2 infection: A series of five cases. Med. 2021;57:412.
16. Roncati L, Lusenti B, Nasillo V, Manenti A. Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease. Ann Hematol. 2020;99(8):1945–6.
17. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.e20.
18. Ruiz-Pablos M, Paiva B, Montero-Mateo R, Garcia N, Zabaleta A. Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. Front Immunol. 2021;12:656797.
19. Cardozo CM, Hainaut P. Viral strategies for circumventing p53: The case of severe acute respiratory syndrome coronavirus. Curr Opin Oncol. 2021;33(2):149–58.
20. Nunn AVW, Guy GW, Botchway SW, Bell JD. SARS-CoV-2 and EBV; the cost of a second mitochondrial “whammy”? Immun Ageing. 2021;18(1):40.
21. Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long covid prevalence and its relationship to epstein-barr virus reactivation. Pathogens. 2021;10:763.
22. Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023;133(3):e163669.
23. Klutts JS, Ford BA, Perez NR, Gronowski AM. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J Clin Microbiol. 2009 Oct;47(10):3204–10.
24. Lanz T V., Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321–7.
25. Robbiani, Davide F CG, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals. Nature [Internet]. 2020;584(7821):437–42. Available from: https://datadryad.org/stash/dataset/doi:10.5061/dryad.35ks2
26. Chen T, Song J, Liu H, Zheng H, Chen C. Positive Epstein–Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2021;11:10902.
27. Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv Prepr Serv Heal Sci. 2022;623(7985):139–48.
28. Rousseau BA, Bhaduri-McIntosh S. Inflammation and Epstein–Barr Virus at the Crossroads of Multiple Sclerosis and Post-Acute Sequelae of COVID-19 Infection. Viruses. 2023;15(4):949.
29. Burton EM, Goldbach-Mansky R, Bhaduri-Mcintosh S. A promiscuous inflammasome sparks replication of a common tumor virus. Proc Natl Acad Sci U S A. 2020;117(3):1722–30.
30. Hashimoto K. Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein–Barr virus and the gut–brain axis. Mol Psychiatry. 2023;
31. Ariza ME. Myalgic encephalomyelitis/chronic fatigue syndrome: The human herpesviruses are back! Biomolecules. 2021;11(2):185.
32. Halpin P, Williams M, Klimas N, Fletcher M, Barnes Z, Ariza M. Myalgic encephalomyelitis/chronic fatigue syndrome and gulf war illness patients exhibit increased humoral responses to the herpesviruses-encoded dUTPase: Implications in disease pathophysiology. J Med Virol. 2017;89(9):1636–45.
33. Ruiz-Pablos M, Paiva B, Zabaleta A. Epstein–Barr virus-acquired immunodeficiency in myalgic encephalomyelitis—Is it present in long COVID? J Transl Med. 2023;21(1):633.